# US 2013/0261122 A1 · Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0261122 A1
- Document ID: US20130261122A1
- Status: Published application
- Kind: A1
- Application number: 13/991,973
- Filed: 2011-12-16
- Published: 2013-10-03
- Earliest claimed: 2010-12-16
- Assignees: N30 Pharmaceuticls, Inc.
- Inventors: Xicheng Sun; Jian Qiu; Adam Stout
- Web page: https://patentgrep.com/patent/US20130261122A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 65/105: polycyclic
- C07C 65/17: containing rings other than six-membered aromatic rings
- C07C 65/24: polycyclic
- C07D 213/79: Acids; Esters
- C07D 215/06: having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
- C07D 215/20: Oxygen atoms
- C07D 215/60: N-oxides
- C07D 217/04: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 217/16: substituted by oxygen atoms
- C07D 237/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 239/26: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 239/28: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D 239/34: One oxygen atom
- C07D 239/74: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 241/42: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 249/18: Benzotriazoles
- C07D 253/10: Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
- C07D 257/04: Five-membered rings
- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/14: containing three or more hetero rings
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12N 9/99: Enzyme inactivation by chemical treatment
- C12N 9/0065: {acting on hydrogen peroxide as acceptor (1.11)}
- C12Y 101/01284: S-(hydroxymethyl)glutathione dehydrogenase (1.1.1.284), i.e. nitroreductase
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

## Claims

### Claim 1

The compound of Formula 1:
Wherein
R1 is selected from the group consisting of H, F, and Cl;
R2a and R2b are independently selected from the group consisting of H, F, Cl, Br, Me, OCH3, and cyano;
R2c is selected from the group consisting of H, F, Cl, Br, Me, and OCH3;
X is selected from the group consisting of
A is selected from the group consisting of
R3 is selected from the group consisting of F, Cl, Br, CH3, CF3, OCH3, cyano, N(CH3)2, and morpholino;
n is selected from the group consisting of 0, 1, and 2;
R4 is selected from the group consisting of H, F, Cl, Br, CH3, CF3, OCH3, cyano, N(CH3)2, and morpholino;
with the proviso that when X is
and A is COOH, then at least one of R1, R2a, R2b, R2c, and R4 is not hydrogen, or n must be >0, and R3 when meta to naphthalene, cannot be CH3.

### Claim 2 (depends on 1)

The compound of claim 1 wherein
X is selected from the group consisting of

### Claim 3 (depends on 1)

The compound of claim 1 wherein X is

### Claim 4 (depends on 3)

The compound of claim 3 wherein R2c is hydrogen.

### Claim 5 (depends on 3)

The compound of claim 3 where R2b is hydrogen.

### Claim 6 (depends on 1)

The compound of claim 1 wherein the compound is a compound of Formula 2

### Claim 7 (depends on 6)

The compound of claim 6 wherein
R1 is selected from the group consisting of H and F;
R2a is selected from the group consisting of H, F, Cl, Br, and cyano;
R2b is selected from the group consisting of H, F, and Cl;
R2c is H; and
R4 is selected from the group consisting of H, F, Cl, and cyano.

### Claim 8 (depends on 6)

The compound of claim 6 wherein R1 is selected from the group consisting of F and Cl.

### Claim 9 (depends on 6)

The compound of claim 6 wherein R2a is selected from the group consisting of F, Cl, Br, Me, OCH3, and cyano.

### Claim 10 (depends on 6)

The compound of claim 6 wherein R2b is selected from the group consisting of F, Cl, Br, Me, OCH3, and cyano.

### Claim 11 (depends on 6)

The compound of claim 6 wherein R2c is selected from the group consisting of F, Cl, Br, Me, and OCH3;

### Claim 12 (depends on 6)

The compound of claim 6 wherein R4 is selected from the group consisting of F, Cl, Br, CH3, CF3, OCH3, cyano, N(CH3)2, and morpholino.

### Claim 13 (depends on 1)

The compound of claim 1 wherein the compound is a compound of Formula 3

### Claim 14 (depends on 13)

The compound of claim 13 wherein X is

### Claim 15 (depends on 14)

The compound of claim 14 where A is COOH.

### Claim 16 (depends on 13)

The compound of claim 13 wherein the compound is a compound of Formula 4

### Claim 17 (depends on 16)

The compound of claim 16 wherein R2c is H.

### Claim 18 (depends on 16)

The compound of claim 16 wherein R2b is H.

### Claim 19 (depends on 16)

The compound of claim 16 wherein
R1 is selected from the group consisting of H and F;
R2b is selected from the group consisting of H, F, and Cl;
R2c is H; and
R4 is selected from the group consisting of H, F, Cl, and cyano.

### Claim 20 (depends on 1)

The compound of claim 1 wherein the compound is a compound of Formula 5

### Claim 21 (depends on 20)

The compound of claim 20 wherein X is

### Claim 22 (depends on 21)

The compound of claim 21 wherein A is COOH.

### Claim 23 (depends on 20)

The compound of claim 20 wherein the compound is a compound of Formula 6

### Claim 24 (depends on 23)

The compound of claim 23 wherein R2c is H.

### Claim 25 (depends on 23)

The compound of claim 23 wherein R2b is H.

### Claim 26 (depends on 23)

The compound of claim 23 wherein
Rea is selected from the group consisting of H, F, Cl, Br, and cyano;
R2b is selected from the group consisting of H, F, and Cl;
R2c is H; and
R4 is selected from the group consisting of H, F, Cl, and cyano.

### Claim 27 (depends on 1)

The compound of claim 1 wherein the compound is selected from the group consisting of
3-chloro-4-(6-hydroxynaphthalen-2-yl)benzoic acid;
3-fluoro-4-(6-hydroxynaphthalen-2-yl)benzoic acid;
4-(6-hydroxynaphthalen-2-yl)-3-methoxybenzoic acid;
3-(dimethylamino)-4-(6-hydroxynaphthalen-2-yl)benzoic acid;
3-cyano-4-(6-hydroxynaphthalen-2-yl)benzoic acid;
4-(6-hydroxynaphthalen-2-yl)-3-morpholinobenzoic acid;
4-(1-bromo-6-hydroxynaphthalen-2-yl)benzoic acid;
4-(6-hydroxy-1-methylnaphthalen-2-yl)benzoic acid;
4-(1-cyano-6-hydroxynaphthalen-2-yl)benzoic acid;
4-(6-hydroxy-3-methoxynaphthalen-2-yl)benzoic acid;
4-(1-chloro-6-hydroxynaphthalen-2-yl)benzoic acid;
6-(4-(1H-tetrazol-5-yl)phenyl)naphthalen-2-ol;
5-(6-hydroxynaphthalen-2-yl)picolinic acid;
6-(6-hydroxynaphthalen-2-yl)nicotinic acid;
5-(6-hydroxynaphthalen-2-yl)pyrazine-2-carboxylic acid;
2-(6-hydroxynaphthalen-2-yl)pyrimidine-5-carboxylic acid;
6-(6-hydroxynaphthalen-2-yl)pyridazine-3-carboxylic acid;
5-(6-hydroxynaphthalen-2-yl)pyrimidine-2-carboxylic acid;
6-(1H-benzo[d][1,2,3]triazol-6-yl)naphthalen-2-ol;
4-(6-hydroxynaphthalen-2-yl)-3-(trifluoromethyl)benzoic acid;
3-chloro-4-(3-fluoro-6-hydroxynaphthalen-2-yl)benzoic acid;
4-(3-chloro-6-hydroxynaphthalen-2-yl)benzoic acid;
4-(3-fluoro-6-hydroxynaphthalen-2-yl)benzoic acid;
4-(6-hydroxy-1-methoxynaphthalen-2-yl)benzoic acid;
4-(1-fluoro-6-hydroxynaphthalen-2-yl)benzoic acid;
4-(6-hydroxy-3-methylnaphthalen-2-yl)benzoic acid;
4-(1-cyano-5-fluoro-6-hydroxynaphthalen-2-yl)benzoic acid;
4-(1-cyano-6-hydroxynaphthalen-2-yl)-3-fluorobenzoic acid;
3-chloro-4-(5-fluoro-6-hydroxynaphthalen-2-yl)benzoic acid;
4-(5-fluoro-6-hydroxynaphthalen-2-yl)benzoic acid;
3-fluoro-4-(5-fluoro-6-hydroxynaphthalen-2-yl)benzoic acid; and
4-(5-fluoro-6-hydroxynaphthalen-2-yl)-3-methylbenzoic acid.

### Claim 28 (depends on 1)

Use of a compound of the Formula 1 as defined in claim 1 or a pharmaceutically acceptable salt thereof as a GSNOR inhibitor.

### Claim 29 (depends on 27)

Use of a compound of claim 27 or a pharmaceutically acceptable salt thereof as a GSNOR inhibitor.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 together with a pharmaceutically accepted carrier or excipient.

### Claim 31 (depends on 1)

A method of treatment of a disease or condition which comprises administering a therapeutically effective amount of a compound of Formula 1 as defined in claim 1 to a patient in need thereof.

### Claim 32 (depends on 1)

A method of making a compound of Formula 1 as defined in claim 1.
